

**Draft agenda**  
**33<sup>rd</sup> meeting of the Biocidal Products Committee (BPC)**  
**10 - 11 December 2019**  
**ECHA Conference Centre, Annankatu 18, Helsinki**  
**Starts on 10 December at 09:30,**  
**ends on 11 December at 18:00**

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-33-2019\_rev2  
*For agreement*

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-31

BPC-M-31-2019  
*For agreement*

5. – Administrative issues

5.1. Housekeeping issues

*For information*

5.2. Other administrative issues and report from other Committees

*For information*

5.3. ECHA Activities Coordination Tool (ACT)

*For information*

## **6. – Work programme for BPC**

- 6.1. BPC Work Programme for active substance approval**  
BPC-33-2019-01  
*For information*
- 6.2. BPC Work Programme for Union authorisation**  
BPC-33-2019-02  
*For information*
- 6.3. Outlook for BPC**  
BPC-33-2019-03  
*For information*
- 6.4. Status ED assessment for active substances**  
BPC-33-2019-04  
*For information*

## **7. – Applications for approval of active substances\***

- 7.1. Procedural and administrative aspects:**
- 7.1.1. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval**  
BPC-33-2019-05  
*For information*
- 7.1.2. Revised opinion template for active substance approval**  
BPC-33-2019-06  
*For agreement*
- 7.1.3. Opinion request Commission pursuant to Article 75(1)(g) on sodium chloride specifications and water quality for the generation of active chlorine by electrolysis**  
BPC-33-2019-07  
*For information*
- 7.2. Follow-up BPC opinion on DBNPA for PT 4 following BPC-31**  
BPC-33-2019-08A,B  
*For agreement*

---

\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

**7.3. Draft BPC opinion on icaridin for PT 19**

*Previous discussion: BPC-28*

BPC-33-2019-09A, B, C

***For adoption***

**7.4. Draft BPC opinion on cyanamide for PT 3 and 18**

*Previous discussion: BPC-16*

**PT 3:** BPC-33-2019-10A, B, C

**PT 18:** BPC-33-2019-11A and BPC-33-2019-10B, C

***For adoption***

**7.5. Draft BPC opinion on formaldehyde for PT 2 and 3**

*Previous discussion: BPC-13*

**PT 2:** BPC-33-2019-12A, B, C

**PT 3:** BPC-33-2019-13A, B, C

***For adoption***

**7.6. Draft BPC opinion on carbendazim for PT 7 and 10**

*Previous discussion: BPC-25*

**PT 7:** BPC-33-2019-14A, B, C

**PT 10:** BPC-33-2019-15A and BPC-33-2019-14 B, C

***For adoption***

**8. – Union authorisation\*\***

**8.1 Update on Union authorisation**

***For information***

**8.1.1 Revised opinion template for Union authorisation**

BPC-33-2019-19

***For agreement***

**8.1.2 Introducing new data during the peer review phase for applications for Union authorisation**

BPC-33-2019-20

***For agreement***

**8.1.3 Implementation of CA document on “Addressing concerns of co-formulants that contribute significantly to a product’s efficacy” (CA-Jan18-Doc.4.2\_final)**

BPC-33-2019-21

***For discussion***

---

\*\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by D).

**8.1.4 Revised procedure “Linguistic review of the translations of the summary of product characteristics (SPC) for Union authorisation applications**

BPC-33-2019-22

***For agreement***

**8.2 Draft BPC opinions on Union authorisation applications for a product family containing propan-2-ol**

*Previous discussion: WG-IV-2019*

BPC-33-2019-23A, B, C, C1, D, E

***For adoption***

**8.3 Draft BPC opinions on Union authorisation applications for a product family containing iodine / PVP-iodine**

*Previous discussion: WG-IV-2019*

BPC-33-2019-24A, B, C, D

***For adoption***

**9. - Any other business**

**9.1 Applying the ECHA Read-Across Assessment Framework in biocides**

BPC-33-2019-25A, B

***For agreement***

**9.2 Request to ECHA on guidance for risk assessment for bees**

BPC-33-2019-26A, B

***For information***

**10. - Action points and conclusions**

***For agreement***

**Provisional time schedule for the  
33<sup>rd</sup> meeting of the Biocidal Products Committee (BPC)  
ECHA Conference Centre, Annankatu 18, Helsinki  
10 December 2019: starts at 09:30; 11 December 2019 ends at 18:00**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

**Tuesday 10 December: morning session**

- |           |  |
|-----------|--|
| Items 1-5 | Opening items and administrative issues  |
| Item 5.3  | ECHA Activities Coordination Tool (ACT)  |
| Item 6    | Work programme for BPC   |
|           | 6.1. BPC Work Programme for active substance approval  |
|           | 6.2. BPC Work Programme for Union authorisation  |
|           | 6.3. Outlook for BPC   |
|           | 6.4. Status ED assessment for active substances  |
| Item 7.1  | Procedural and administrative aspects:   |
|           | 7.1.1. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval                           |
|           | 7.1.2. Revised opinion template for active substance approval  |
|           | 7.1.3. Opinion request Commission pursuant to Article 75(1)(g) on sodium chloride specifications and water quality for the generation of active chlorine by electrolysis |
| Item 7.2  | Follow-up BPC opinion on DBNPA for PT 4 following BPC-31   |
| Item 7.3  | Draft BPC opinion on icaridin for PT 19  |

**Tuesday 10 December: afternoon session**

- |          |   |
|----------|---|
| Item 7.4 | Draft BPC opinion on cyanamid for PT 3 and 18   |
| Item 7.5 | Draft BPC opinion on formaldehyde for PT 2 and 3  |
| Item 7.6 | Draft BPC opinion on carbendazim for PT 7 and 10  |
| Item 8.1 | Update on Union authorisation   |
|          | 8.1.1. Revised opinion template for Union authorisation   |
|          | 8.1.2. Introducing new data during the peer review phase for applications for Union authorisation   |
|          | 8.1.3. Implementation of CA document on "Addressing concerns of co-formulants that contribute significantly to a product's efficacy" (CA-Jan18-Doc.4.2_final) |
|          | 8.1.4. Revised procedure "Linguistic review of the translations of the summary of product characteristics (SPC) for Union authorisation applications          |

**Wednesday 11 December: morning session**

- Item 8.2                    Draft BPC opinions on Union authorisation applications for a product family containing propan-2-ol
- Item 8.3                    Draft BPC opinions on Union authorisation applications for a product family containing iodine / PVP-iodine

**Wednesday 11 December: afternoon session**

- Item 9.1                    Introduction of ECHA Read-across assessment framework in biocides
- Item 9.2                    Request to ECHA on guidance for risk assessment for bees
- Item 10                    Action points and conclusions

End of meeting

oOo